Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ALN-TTRSC04

Oligonucleotide (siRNA) · Gene silencing: transthyretin (TTR) · developed by ALNYLAM PHARMACEUTICALS

Phase 1 Most advanced trial (none active)
ALNY Developer
1 Registered trials

What is ALN-TTRSC04?

ALN-TTRSC04 is a small interfering RNA administered by subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
transthyretin (TTR)
Mechanism
Gene silencing: transthyretin (TTR)
Therapy area
Cardiovascular
Developer
ALNYLAM PHARMACEUTICALS (ALNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05661916 Phase 1 Transthyretin-Mediated Amyloidosis Completed ALNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Transthyretin-Mediated Amyloidosis

Other drugs acting on TTR

More from ALNYLAM PHARMACEUTICALS

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALNY page.

Follow ALNY, the company behind ALN-TTRSC04

See ALNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.